CDP 870: Phase II results in rheumatoid arthritis*

• 3 doses/12 wks (sc)

• no methotrexate

Dose-ranging study in

203 patients

ACR 20

(p=0.001)

0

10

20

30

40

50

60

70

CDP870

400mg

Enbrel 25mg

D2E7 40mg

Remicade

10mg/kg

+MTX

0

10

20

30

40

50

60

70

80

D2E7 40mg

CDP870

400mg

Enbrel 25mg

ACR 50

(p=0.001)

Remicade

10mg/kg

+MTX

ACR 70

(p=0.014)

0

10

20

30

40

50

60

70

80

D2E7 40mg

CDP870

400mg

Enbrel 25mg

na

dosing

interval

2 wks

4 wks

2 x per wk

Remicade

10mg/kg

+MTX

8 wks

data point

12 wks

12 wks

24 wks

54 wks

* Per protocol data; presented

at ACR Meeting, San Francisco

(Nov 2001)

Previous slide

Next slide

Back to first slide

View graphic version